Literature DB >> 21454205

High-throughput genomic analysis in Waldenström's macroglobulinemia.

Stéphanie Poulain1, Esteban Braggio, Christophe Roumier, Rachid Aijjou, Natacha Broucqsault, Sylvie Galiègue-Zouitina, Salomon Manier, Valérie Soenen, Olivier Nibourel, Patrick Duthilleul, Rafael Fonseca, Xavier Leleu.   

Abstract

Single-nucleotide polymorphism array (SNPa) and array-based comparative genomic hybridization (aCGH) are among the most sensitive genomic high-throughput screening techniques used in the exploration of genetic abnormalities in Waldenström's macroglobulinemia (WM). SNP and aCGH allow the identification of copy number abnormalities (CNA) at the kilobase level thus identifying cryptic genetic abnormalities unseen by lower-resolution approaches such as conventional cytogenetic or fluorescence in situ hybridization (FISH). CNA were identified in nearly 80% of cases by aCGH that delineated in addition minimal altered regions. At gene level, remarkable findings affecting genes involved in the regulation of the NF-kB signaling pathways were identified, such as biallelic inactivation of TNFAIP3 and TRAF3. SNPa also allowed characterization of copy neutral losses such as uniparental disomies (UPD), which is an important and frequent mechanism of gene alteration in cancer cells. Herein, we summarize the current knowledge of WM genomic basis using these high-throughput techniques.

Entities:  

Mesh:

Year:  2011        PMID: 21454205     DOI: 10.3816/CLML.2011.n.021

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  8 in total

Review 1.  TRAF3, ubiquitination, and B-lymphocyte regulation.

Authors:  Wai W Lin; Bruce S Hostager; Gail A Bishop
Journal:  Immunol Rev       Date:  2015-07       Impact factor: 12.988

2.  A Complex Relationship between TRAF3 and Non-Canonical NF-κB2 Activation in B Lymphocytes.

Authors:  Wai W Lin; Joanne M Hildebrand; Gail A Bishop
Journal:  Front Immunol       Date:  2013-12-20       Impact factor: 7.561

Review 3.  Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.

Authors:  Daniela Drandi; Philippe Decruyenaere; Martina Ferrante; Fritz Offner; Jo Vandesompele; Simone Ferrero
Journal:  Diagnostics (Basel)       Date:  2022-04-12

Review 4.  Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies.

Authors:  Ava J Boutilier; Lina Huang; Sherine F Elsawa
Journal:  Int J Mol Sci       Date:  2022-09-22       Impact factor: 6.208

Review 5.  How to manage Waldenstrom's macroglobulinemia.

Authors:  C Buske; V Leblond
Journal:  Leukemia       Date:  2013-02-06       Impact factor: 11.528

6.  Candidate genes of Waldenström's macroglobulinemia: current evidence and research.

Authors:  Giada Bianchi; Antonio Sacco; Shaji Kumar; Giuseppe Rossi; Irene Ghobrial; Aldo Roccaro
Journal:  Appl Clin Genet       Date:  2013-07-17

7.  MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemia.

Authors:  Jung-Ah Kim; Kyongok Im; Si Nae Park; Jiseok Kwon; Qute Choi; Sang Mee Hwang; Naohiro Sekiguchi; Sung-Soo Yoon; Dong Soon Lee; Seon Young Kim
Journal:  Biomed Res Int       Date:  2014-05-07       Impact factor: 3.411

Review 8.  MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.

Authors:  Veronica Tisato; Rebecca Voltan; Arianna Gonelli; Paola Secchiero; Giorgio Zauli
Journal:  J Hematol Oncol       Date:  2017-07-03       Impact factor: 17.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.